Microemulsions as precursors to solid nanoparticles

• US 7,153,525 B1
• Filed: 03/21/2001
• Issued: 12/26/2006
• Est. Priority Date: 03/22/2000
• Status: Expired due to Term

• Current Assignee: Particle Sciences, Inc. (Agno Pharma)
• Original Assignee: University Of Kentucky Research Foundation (University of Kentucky)
• Inventors: Mumper, Russell John, Jay, Michael
• Primary Examiner(s): Hartley, Michael
• Assistant Examiner(s): YOUNG, MICAH PAUL
• Application Number:
  US09/812,884
• Publication Number:
  US 20060292183A1
• Time in Patent Office: 2,106 Days
• Field of Search: 424489-491, 424/499, 424/450, 424/401, 424/498, 424/400, 514937-939, 514/393, 264 41- 44, 264/5
• US Class Current: 424/489
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/5123 Organic compounds, e.g. fats, sugars
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The preparation of novel microemulsions to be used as precursors for solid nanoparticles is described. The microemulsion precursors consist of either alcohol-in-fluorocarbon microemulsions, liquid hydrocarbon-in-fluorocarbon microemulsions, or liquid hydrocarbon-in-water microemulsions. The formed solid nanoparticles have diameters below 200 nanometers and can be made to entrap various materials including drugs, magnets, and sensors. The solid nanoparticles can be made to target different cells in the body by the inclusion of a cell-specific targeting ligand. Methods of preparing the novel microemulsion precursors and methods to cure solid nanoparticles are provided.

Claims

1. A method of making solid nanoparticles, comprising:

making an oil-in-water microemulsion by heating, the microemulsion comprising;

a liquid nanoparticle matrix material formed by heating a solid matrix material until melted;

a surfactant or a co-surfactant or a mixture thereof, and

a molecule of interest, wherein the molecule is a drug molecule;

wherein the microemulsion is formed essentially spontaneously by heating at a temperature of between about 35°

C. and about 100°

C.; and

cooling the microemulsion while stirring to form solid nanoparticles having a diameter of less than about 300 nanometers, wherein said solid nanoparticles are formed by cooling the microemulsion without aqueous dilution, and where the molecule of interest is either entrapped in or adsorbed to the solid nanoparticles.

2. The method according to claim 1, wherein the nanoparticle matrix material comprises one or more of the following materials:

emulsifying wax, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene stearates, phospholipids, fatty acids or fatty alcohols or their derivatives, or combinations thereof.

3. The method according to claim 1, wherein the liquid nanoparticle matrix material is present in the microemulsion at a concentration from about 0.1 to about 30 mg/mL.

4. The method according to claim 1, wherein the microemulsion comprises an oil phase that is present as liquid droplets having a diameter of less than about 100 nanometers.

5. The method according to claim 1, wherein the microemulsion comprises a continuous phase comprising water or an aqueous buffer at a concentration of greater than about 95% w/w.

6. The method according to claim 1, wherein the surfactant or co-surfactant comprises polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, hexadecyltrimethylammonium bromide, fatty alcohol and their derivatives, or combinations, thereof.

7. The method according to claim 1, wherein the surfactant is present at a total concentration of about 1–

5000 mM.

8. The method according to claim 1, wherein the molecule of interest is present at a total concentration in the range of about 20 μ

g/mL to about 5 mg/mL.

9. The method according to claim 1, wherein the nanoparticle is coated with a cell-specific ligand such as an antibody, carbohydrate, peptide, protein, or derivatives or combinations thereof.

10. The method of claim 1, wherein the nanoparticles and molecule of interest are formulated into a pharmaceutical composition suitable for intravenous, intramuscular or subcutaneous administration.